Cite
MLA Citation
T. Schindler et al.. “AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN).” Annals of the rheumatic diseases, vol. 75, n.d., p. 1051. http://access.bl.uk/ark:/81055/vdc_100135160845.0x000057